Purpose Aggressive prolactinomas are defined as radiologically invasive tumors which
cannot be cured by surgery, and that have an unusually rapid rate of tumor growth despite …

Introduction Aggressive prolactinomas are life-limiting tumors without a standard of care
treatment option after the oral alkylator, temozolomide, fails to provide tumor control …

Most prolactin-secreting pituitary adenomas demonstrate slow growth and are effectively
managed with medical/surgical therapy. Rarely, these tumors can behave aggressively with …

Objective Invasive, medically refractory, and multiply recurrent pituitary adenomas pose a
rare, but nevertheless significant, challenge for conventional management modalities …

Introduction: Aggressive tumors of the pituitary gland are classically defined as pituitary
tumors with a massive invasion of the surrounding anatomical structures and rapid growth …

Prolactinomas constitute the largest group of pituitary adenomas in autopsy series.
However, their relative incidence in recent surgical series is much less impressive since …

Giant prolactinomas are rare tumours, representing only 2–3% of all prolactin (PRL)-
secreting tumours and raising special diagnostic and therapeutic challenges. Based on …

Background The majority of prolactinomas respond to dopamine agonist therapy, but a
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …

Prolactinomas, the most prevalent type of neuroendocrine disease, account for
approximately 40% of all pituitary adenomas. The most important clinical problems …

Dopamine agonists (DAs, especially cabergoline) are recommended as first-line treatment
in patients with prolactin-secreting pituitary adenomas, to reduce hormone secretion and …